A large Welsh study reveals that maternal depression during pregnancy is associated with increased neurodevelopmental difficulties in children, regardless of whether the mother took antidepressants, intensifying ongoing debates on managing depression in pregnancy.
Maternal depression during pregnancy is linked to a higher likelihood of neurodevelopmental difficulties in children, whether or not the mother took antidepressants, according to a large study from Wales published in PLOS Medicine. The findings add to a long-running debate over how to balance the risks of untreated depression against concerns about medication exposure in pregnancy.
Researchers led by Saraid McIlvride at the University of Glasgow analysed records for 167,447 children born between 2009 and 2016 and followed them through to 2022. They looked at special educational needs, a broad category that includes autism spectrum disorder, ADHD, learning difficulties, sensory impairment and social, emotional, communication, physical and mental difficulties.
The study found that maternal depression was associated with a higher risk of special educational needs, and antidepressant exposure was also linked to increased risk. Children whose mothers had both depression and antidepressant treatment had the highest predicted probability of special educational needs. But the pattern also suggested that depression itself plays a major role, because children exposed to untreated maternal depression still faced elevated risk compared with those whose mothers were not depressed.
The researchers said the evidence base has been difficult to interpret because earlier studies have been inconsistent and often limited by design. They also noted that they did not have detailed information on the severity of depression, which matters because stronger antidepressants or second-line drugs may be more likely to be used in more severe illness. That leaves open the possibility that medication use is partly a marker for worse underlying depression rather than a direct cause of later developmental problems.
Their conclusions echo previous research. A systematic review and meta-analysis published in The Lancet Psychiatry found a modest association between prenatal antidepressant use and neurodevelopmental disorders such as ADHD and autism, but also stressed the need for caution in interpreting cause and effect. Earlier studies have similarly suggested that children exposed to antidepressants in the womb may have outcomes similar to those of children exposed to untreated maternal depression, and worse than those of children born to mothers without depression.
The findings come amid renewed scrutiny of selective serotonin reuptake inhibitors, or SSRIs, during pregnancy. But the broader clinical context remains that untreated maternal depression can itself be harmful. Experts quoted by Healio said the risks of leaving depression unmanaged outweigh the potential risks of SSRIs, and earlier research has linked stopping antidepressants during pregnancy with a higher risk of mental health emergencies. The Welsh data, taken together with prior sibling-comparison analyses, point to a complicated picture in which genetic, familial and illness-related factors may matter as much as, or more than, the medicines themselves.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
